,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-08-01 02:26:00,The Zacks Research Daily presents the best research output of our analyst team.,0.6325156092643738,0.012341027148067951,0.35514333844184875,positive,0.6201745867729187
1,2017-08-01 02:26:00,"Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Altria (MO) and Bristol-Myers (BMY).",0.04551798850297928,0.007685892283916473,0.9467961192131042,neutral,0.037832096219062805
2,2017-08-01 02:26:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
3,2017-08-01 02:26:00,"You can see all of today's research reports here >>>

Buy-rated Procter & Gamble shares have outperformed the Zacks Consumer Staples sector in the past year (+4.8% vs. +2.1%).",0.7959122061729431,0.1748461276292801,0.029241641983389854,positive,0.6210660934448242
4,2017-08-01 02:26:00,"However, P&G shares have underperformed the S&P 500 index in the year-to-date period (up +8.1% vs. +10.5%).",0.2713909447193146,0.708956241607666,0.0196528397500515,negative,-0.43756529688835144
5,2017-08-01 02:26:00,P&G's earnings and revenues surpassed expectations in fourth-quarter fiscal 2017.,0.9467010498046875,0.01840164139866829,0.03489729389548302,positive,0.9282994270324707
6,2017-08-01 02:26:00,Adjusted earnings increased 8% year over year but net sales remained unchanged with the year-ago level.,0.9202502965927124,0.04211103916168213,0.037638649344444275,positive,0.8781392574310303
7,2017-08-01 02:26:00,The company has been struggling to boost market growth for the last few quarters.,0.04908083751797676,0.9198678731918335,0.03105132281780243,negative,-0.8707870244979858
8,2017-08-01 02:26:00,But the Zacks analyst likes the fact that P&G is speeding up innovations and investments to counter softening industry growth.,0.8218693733215332,0.017717216163873672,0.16041336953639984,positive,0.8041521310806274
9,2017-08-01 02:26:00,"Its productivity improvements and aggressive cost-saving efforts, projected to save $10 billion over the next five years, are also consistently helping to boost profit levels.",0.9534759521484375,0.020016031339764595,0.02650798298418522,positive,0.9334599375724792
10,2017-08-01 02:26:00,(You can read the full research report on Procter & Gamble here >>> ) .,0.013788774609565735,0.010992237366735935,0.9752189517021179,neutral,0.0027965372428297997
11,2017-08-01 02:26:00,"Sharesof Altria have lagged the Zacks Tobacco industry in the year-to-date period, with the stock down -3.1% vs. the peer group's +12.2% gain.",0.019161920994520187,0.9691972732543945,0.011640825308859348,negative,-0.9500353336334229
12,2017-08-01 02:26:00,Both Altria's earnings and revenues grew year-over-year in the second quarter 2017 driven by strong cigarette pricing and increase in smokeless products.,0.954906702041626,0.017146652564406395,0.027946678921580315,positive,0.937760055065155
13,2017-08-01 02:26:00,"Altria, the U.S.-based entity whose international sibling is Phillips Morris International (PM), is operating in a mature and heavily regulated market that has been undergoing consistent volume declines over the last many years.",0.028558172285556793,0.9291070103645325,0.042334798723459244,negative,-0.9005488157272339
14,2017-08-01 02:26:00,But the strength of Marlboro brand and a solid portfolio or low-risk smokeless tobacco products positions it to profitably navigate this market.,0.925884485244751,0.014295543543994427,0.05981991067528725,positive,0.9115889668464661
15,2017-08-01 02:26:00,"Further, the takeover of SABMiller by Anheuser-Busch InBev has helped Altria maximize the value of its SABMiller investment.",0.9464806914329529,0.014113855548202991,0.0394054614007473,positive,0.9323668479919434
16,2017-08-01 02:26:00,"An attractive dividend, currently yielding 3.8%, is a notable part of this story as well.",0.4126851260662079,0.010327736847102642,0.5769871473312378,neutral,0.40235739946365356
17,2017-08-01 02:26:00,(You can read the full research report on Altria here >>> ) .,0.014041485264897346,0.01390156801789999,0.9720569252967834,neutral,0.00013991724699735641
18,2017-08-01 02:26:00,"Bristol-Myers 's shares have underperformed the broader market as well as the large cap pharma group this year, losing -2.5% in the year-to-date period.",0.020816268399357796,0.9690244197845459,0.010159337893128395,negative,-0.9482081532478333
19,2017-08-01 02:26:00,"Bristol-Myers delivered yet another strong quarter with the top and the bottom line beating expectations driven by sales of drugs like Opdivo, Eliquis and Yervoy.",0.9474436044692993,0.027462996542453766,0.025093385949730873,positive,0.9199805855751038
20,2017-08-01 02:26:00,"Meanwhile, Bristol-Myers is looking to expand Opdivo's label further which should boost performance.",0.9546923637390137,0.017517438158392906,0.02779012732207775,positive,0.937174916267395
21,2017-08-01 02:26:00,"However, Opdivo is currently facing competitive challenges in the U.S. With the FDA approving Merck's Keytruda, for the first-line treatment of metastatic nonsquamous NSCLC, the company is expected to see further loss of market share.",0.017124118283391,0.9602879881858826,0.022587858140468597,negative,-0.9431638717651367
22,2017-08-01 02:26:00,Shares were down after Q2 results as concerns from AstraZeneca's failed study on lung cancer drug Imfinzi loomed large on the company's CheckMate 227 study on Opdivo.,0.017411643639206886,0.9667989611625671,0.01578948274254799,negative,-0.9493873119354248
23,2017-08-01 02:26:00,(You can read the full research report on Bristol-Myers here >>> ) .,0.013764891773462296,0.012010612525045872,0.9742245078086853,neutral,0.0017542792484164238
24,2017-08-01 02:26:00,"Other noteworthy reports we are featuring today include Stryker (SYK), ConocoPhillips (COP) and Electronic Arts (EA).",0.030199246481060982,0.005774886813014746,0.9640258550643921,neutral,0.02442435920238495
25,2017-08-01 02:26:00,"Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar.",0.04345273599028587,0.020456276834011078,0.9360910058021545,neutral,0.022996459156274796
26,2017-08-01 02:26:00,Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential?,0.33031973242759705,0.014298503287136555,0.6553817391395569,neutral,0.31602123379707336
27,2017-08-01 02:26:00,This Special Report gives you the current scoop on 5 that may go public at any time.,0.019046178087592125,0.008929912000894547,0.9720239043235779,neutral,0.010116266086697578
28,2017-08-01 02:26:00,One has driven from 0 to a $68 billion valuation in 8 years.,0.6626474857330322,0.01823992282152176,0.319112628698349,positive,0.6444075703620911
29,2017-08-01 02:26:00,Four others are a little less obvious but already show jaw-dropping growth.,0.2814808785915375,0.08773558586835861,0.6307835578918457,neutral,0.19374528527259827
30,2017-08-01 02:26:00,"Download this IPO Watch List today for free >>

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings.",0.10394110530614853,0.007611018139868975,0.8884479403495789,neutral,0.09633008390665054
31,2017-08-01 02:26:00,He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports.,0.026142945513129234,0.011532393284142017,0.9623246192932129,neutral,0.014610552228987217
32,2017-08-01 02:26:00,"If you want an email notification each time Sheraz publishes a new article, please click here>>>

Per the Zacks analyst, while approval of new products in the generic segment and biosimilars should boost top-line, EpiPen woes will weigh on shares for Mylan as sales decline due to competition.",0.022992204874753952,0.9612928032875061,0.015714935958385468,negative,-0.938300609588623
33,2017-08-01 02:26:00,"Roche (RHHBY) Sales in 1H17 Strong On Back of New Launches

Roche's sales in 1H17 were solid drive by new drug launches like Tecentriq and Ocrevus.",0.9432814121246338,0.03085418976843357,0.02586432918906212,positive,0.9124272465705872
34,2017-08-01 02:26:00,"Per the Zacks analyst, while the oncology portfolio is solid, competition from biosimilars looms on key drugs.",0.7533474564552307,0.03944636881351471,0.207206130027771,positive,0.7139011025428772
35,2017-08-01 02:26:00,"Per the Zacks analyst, PG&E Corp's multi-billion dollar investment plans in infrastructural development will allow it to add more customers.",0.9378839135169983,0.014645032584667206,0.04747107997536659,positive,0.9232388734817505
36,2017-08-01 02:26:00,"The Zacks analyst thinks Xilinx is focused on tapping fast-growing technologies like AI, 5G connectivity, autonomous vehicles and IoTs to drive growth over the long run.",0.8570387363433838,0.01226620189845562,0.13069503009319305,positive,0.8447725176811218
37,2017-08-01 02:26:00,"Huge acreage holdings in the prospective Eagle Ford shale play will contribute to ConocoPhillips' oil production growth, per the Zacks analyst.",0.8155474066734314,0.011654384434223175,0.17279820144176483,positive,0.8038930296897888
38,2017-08-01 02:26:00,"Per the Zacks analyst, improving assets under management and efforts to lower expenses keep Invesco well poised to improve profitability.",0.9559943079948425,0.02010307088494301,0.023902637884020805,positive,0.9358912110328674
39,2017-08-01 02:26:00,"Per the Zacks analyst, lower margin pressure given the higher interest rates should support revenue growth.",0.9498558044433594,0.01818876527249813,0.031955424696207047,positive,0.9316670298576355
40,2017-08-01 02:26:00,The Zacks analyst believes solid performance in Stryker's MAKO platform drove second-quarter revenues.,0.9569284319877625,0.02012528106570244,0.02294623851776123,positive,0.9368031620979309
41,2017-08-01 02:26:00,An upbeat guidance for the full year instills investor confidence in the stock.,0.9195252060890198,0.020351549610495567,0.06012320518493652,positive,0.8991736769676208
42,2017-08-01 02:26:00,"The Zacks analyst opines that growing digital business, strength in franchises (like EA Sports titles, Battlefield and Star Wars) and cost optimization initiatives will boost revenues going forward.",0.956988513469696,0.01925220713019371,0.023759284988045692,positive,0.9377363324165344
43,2017-08-01 02:26:00,"Per the Zacks analyst, Franklin's efforts to drive operational efficiency remain encouraging.",0.9395208954811096,0.014236854389309883,0.046242330223321915,positive,0.9252840280532837
44,2017-08-01 02:26:00,It also continues to benefit from a strong capital position and diversification.,0.8937203884124756,0.012559706345200539,0.09371989965438843,positive,0.8811606764793396
45,2017-08-01 02:26:00,The Zacks analyst is worried about Energy Transfer's $3.8 billion Dakota project which is grappling with censure and legal snags that might lead to the shutdown of the pipeline operations.,0.020671213045716286,0.9572831392288208,0.022045649588108063,negative,-0.9366119503974915
46,2017-08-01 02:26:00,The Zacks analyst is worried about Zimmer suffering from issues like product supply shortage leading to inability in gaining new customers.,0.024515368044376373,0.9560843110084534,0.019400332123041153,negative,-0.9315689206123352
47,2017-08-01 02:26:00,Stepping down of decade-old CEO is another major concern.,0.032444700598716736,0.8399495482444763,0.12760576605796814,negative,-0.8075048327445984
48,2017-08-01 02:26:00,High costs are hurting the company's bottom-line.,0.019421197474002838,0.9625253677368164,0.018053410574793816,negative,-0.9431041479110718
49,2017-08-01 02:26:00,"Adverse foreign currency movements too represent a major headwind, according to the Zacks analyst.",0.023305099457502365,0.9539209008216858,0.022773917764425278,negative,-0.9306157827377319
50,2017-08-01 02:26:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
51,2017-08-01 02:26:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
52,2017-08-01 02:26:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
53,2017-08-01 02:26:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
